Source comparison
NAD+ Precursors: NMN vs NR vs Liposomal NAD+
NMN (Nicotinamide Mononucleotide) Converted to NR in gut, then to NAD+ intracellularly 250–1000mg daily 2–4 weeks Most studied precursor with human clinical trial data showing 40% NAD+ increase in muscle tissue NR (Nicotinamide Riboside) Direct cellular uptake
This comparison does not assign a generated winner or score.
- NMN (Nicotinamide Mononucleotide)
- Converted to NR in gut, then to NAD+ intracellularly
- 250–1000mg daily
- 2–4 weeks
- Most studied precursor with human clinical trial data showing 40% NAD+ increase in muscle tissue
- NR (Nicotinamide Riboside)
- Direct cellular uptake via nucleoside transporters
- 300–1000mg daily
- 1–2 weeks
- Faster absorption but shorter half-life. May require twice-daily dosing
- Liposomal NAD+
- Phospholipid encapsulation bypasses first-pass metabolism
- 50–200mg daily
- 3–7 days
- Highest bioavailability but most expensive. Clinical data limited compared to NMN/NR
- Nicotinamide (NAM)
- Salvage pathway substrate but inhibits sirtuins at high doses
- 500–1000mg daily
- Variable
- Cheaper but less effective due to sirtuin inhibition feedback loop
- The precursor you choose determines how quickly NAD+ levels rise and which tissues benefit most. NMN has the strongest clinical evidence for muscle and liver NAD+ restoration, while liposomal NAD+ shows promise for rapid cognitive effects due to enhanced blood-brain barrier penetration. NR works faster but may require higher total daily doses to match NMN's tissue accumulation.
- Our team has observed that individuals over 50 respond better to NMN doses above 500mg daily, while younger users (30–40) show measurable improvements at 250–300mg. This aligns with age-related NAD+ depletion curves. Older individuals have deeper deficits that require higher precursor loading to overcome.